Vidac Pharma Holding PLC

Vidac Pharma’s VDA‑1102 compassionate‑use case at the Eilat Paediatric Cancer Symposium shows real‑world success for a rare ependymoma, highlighting the company’s rapid‑translation potential in metabolic and dermatologic oncology.

Vidac Pharma’s first patient dose in Phase‑2b VDA‑1102 for high‑risk actinic keratosis marks a pivotal milestone, advancing a promising dermatologic therapy.